Kevin Fay, MD
He/Him/His
Renal Electrolyte and Hypertension
Accepting new patients
Sees patients age 18 and up
Penn Renal Electrolyte and Hypertension University City
Headshot of Kevin Fay, MD
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Medicine (Renal-Electrolyte and Hypertension)

Education and training

  • Medical School: Ross University School of Medicine
  • Residency: Henry Ford Hospital
  • Fellowship: University of Pennsylvania Health System
  • Fellowship: Thomas Jefferson University Hospital

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: On the medical staff, but does not have privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Penn Medicine Rittenhouse Long-Term Acute Care Hospital
  • Lancaster General Hospital
  • Princeton Medical Center: Has privileges to treat patients in the hospital.
  • Chester County Hospital: Has privileges to treat patients in the hospital.
Dr. Fay is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Kevin S. Fay and Debbie L. Cohen Aldosteronism , Ferri's Clinical Advisor 2022: 2021,103-104


Fay KS, Cohen DL. Resistant Hypertension in People With CKD: A Review , Am J Kidney Dis, 77(1): 2021,110-121


Rao B, Franzo-Romain M, Fay K, Whitlow K, Alam A. An unusual suspect for acute kidney injury in an end-stage liver disease patient: cryoglobulinemic glomerulonephritis , Abstract and Poster Presentation, 39th Annual Meeting of the Society of General Internal Medicine, Hollywood, FL.: 2016


Fay K, Gentile J, Mohyi M, Hrabec D, Bradley P Socioeconomic disparities in completion of open access colonoscopy. , Abstract and Oral Presentation, Henry Ford Hospital 23rd Medical Education Research Forum, Detroit, MI.: 2016


Veine DM, Yao H, Stafford DR, Fay KS, Livant DL. A D-amino acid containing peptide as a potent, noncovalent inhibitor of α5β1 integrin in human prostate cancer invasion and lung colonization , Clin Exp Metastasis, 31(4): 2014,379-93


Livant D, Yao H, Veine D, Fay K. The PHSCN peptide as a highly potent inhibitor of basement membrane invasion in vitro and lung colonization in nude mice by metastatic human prostate cancer cells , Abstract and Poster Presentation, American Association for Cancer Research 103rd Annual Meeting, Chicago, IL: 2012


Yao H, Zeng ZZ, Fay KS, Veine DM, Staszewski ED, Morgan M, Wilder-Romans K, Williams TM, Spalding AC, Ben-Josef E, Livant DL. Role of α(5)β(1) Integrin Up-regulation in Radiation-Induced Invasion by Human Pancreatic Cancer Cells , Transl Oncol, 4(5): 2011,282-92


Yao H, Veine DM, Fay KS, Staszewski ED, Zeng ZZ, Livant DL. The PHSCN dendrimer as a more potent inhibitor of human breast cancer cell invasion, extravasation, and lung colony formation , Breast Cancer Res Treat, 125(2): 2011,363-75


View all publications